piracetam has been researched along with Cerebrovascular Disorders in 29 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Cerebrovascular Disorders: A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since its introduction in 2006, 43 patients with various forms of status epilepticus (SE) have been treated with the intravenous formulation of levetiracetam (LEV) in our clinic." | 7.75 | Two years of experience in the treatment of status epilepticus with intravenous levetiracetam. ( Eue, S; Grumbt, M; Müller, M; Schulze, A, 2009) |
| "GABA and Piracetam caused the improvement of the morphological state of cerebral infarction, due to intracarotid infusion of Arachidonic acid." | 7.68 | [Effects of GABA and piracetam on the development of experimental cerebral infarction in rats and platelet aggregation in patients with cerebrovascular disorders]. ( Amroian, EA; Balian, LS; Parsamian, LK; Vartazarian, ND, 1990) |
| "Piracetam has been shown to improve speech in aphasic patients." | 6.40 | The role of piracetam in the treatment of acute and chronic aphasia. ( Huber, W, 1999) |
| " It covers firstly the general problems of stroke, dementia and 'common symptoms' of the elderly, and then looks in detail at those compounds which have to date attracted most attention (ergot derivatives, cinnarizine, flunarizine, vincamine, eburnamonine, naftidrofuryl, oxpentifylline, piracetam and citicoline), as well as those which are currently considered investigational (choline and lecithin)." | 6.15 | 'Cerebroactive' drugs. Clinical pharmacology and therapeutic role in cerebrovascular disorders. ( Spagnoli, A; Tognoni, G, 1983) |
| "Since its introduction in 2006, 43 patients with various forms of status epilepticus (SE) have been treated with the intravenous formulation of levetiracetam (LEV) in our clinic." | 3.75 | Two years of experience in the treatment of status epilepticus with intravenous levetiracetam. ( Eue, S; Grumbt, M; Müller, M; Schulze, A, 2009) |
| "GABA and Piracetam caused the improvement of the morphological state of cerebral infarction, due to intracarotid infusion of Arachidonic acid." | 3.68 | [Effects of GABA and piracetam on the development of experimental cerebral infarction in rats and platelet aggregation in patients with cerebrovascular disorders]. ( Amroian, EA; Balian, LS; Parsamian, LK; Vartazarian, ND, 1990) |
| " Safety was assessed taking into account adverse events including abnormal laboratory test results and mortality." | 2.69 | The clinical safety of high-dose piracetam--its use in the treatment of acute stroke. ( De Reuck, J; Van Vleymen, B, 1999) |
| " Individualization of dosage and avoidance of unnecessary polypharmacy are essential for safe utilization of anti-epileptic drugs." | 2.44 | [Epilepsy in the elderly]. ( Yoshino, A, 2007) |
| "Piracetam has been shown to improve speech in aphasic patients." | 2.40 | The role of piracetam in the treatment of acute and chronic aphasia. ( Huber, W, 1999) |
| "Acute cerebral ischemia was discovered to be the most common cerebrovascular disease associated with SARS-CoV-2." | 1.72 | Coexistence of SARS-CoV-2 and cerebrovascular diseases: does COVID-19 positivity trigger cerebrovascular pathologies? ( Ates, O; Dogan, M; Ersoz, E; Hacioglu Kasim, FB; Karaarslan, N; Ozbek, H; Yilmaz, I, 2022) |
| "Treatment with oxiracetam (400 mg/kg/d p." | 1.28 | Effect of oxiracetam on cerebrovascular impairment in rats. ( Hasegawa, Y; Inukai, T; Kometani, M; Nakao, N; Okada, M; Takemori, E, 1991) |
| "Piracetam was applied to the treatment of 60 patients with initial manifestations of brain circulation failure and stage I circulatory encephalopathy." | 1.28 | [Significance of subjective symptoms and diagnostic criteria in initial forms of cerebral circulation insufficiency]. ( Berzina, AIa; Eninia, GI; Maĭore, IKh; Purinia, IV; Robule, VKh; Timofeeva, TN, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (27.59) | 18.7374 |
| 1990's | 13 (44.83) | 18.2507 |
| 2000's | 7 (24.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Ates, O | 1 |
| Yilmaz, I | 1 |
| Karaarslan, N | 1 |
| Ersoz, E | 1 |
| Hacioglu Kasim, FB | 1 |
| Dogan, M | 1 |
| Ozbek, H | 1 |
| Zakharov, VV | 1 |
| Lokshina, AB | 1 |
| Stakhovskaia, LV | 1 |
| Timerbaeva, SL | 1 |
| Lagoda, OV | 1 |
| Filimonov, VA | 1 |
| Kliueva, VN | 1 |
| Kondrasheva, IN | 1 |
| Batysheva, TT | 2 |
| Bagir', LV | 2 |
| Kostenko, EV | 2 |
| Artemova, IIu | 1 |
| Bdovichenko, TV | 1 |
| Gazhula, PA | 1 |
| Zhuravleva, EIu | 1 |
| Ismailov, AM | 2 |
| Lisenker, LN | 2 |
| Nesterova, OV | 2 |
| Otcheskaia, OV | 1 |
| Rotor, LD | 2 |
| Khozova, AA | 2 |
| Boĭko, AN | 2 |
| Artemova, IY | 1 |
| Vdovichenko, TV | 1 |
| Ganzhula, PA | 1 |
| Zhuravleva, EY | 1 |
| Otcheskaya, OV | 1 |
| Eue, S | 1 |
| Grumbt, M | 1 |
| Müller, M | 1 |
| Schulze, A | 1 |
| Yoshino, A | 1 |
| Bugrova, SG | 1 |
| Novikov, AE | 1 |
| Wittenborn, JR | 1 |
| Spagnoli, A | 1 |
| Tognoni, G | 1 |
| Man'kovskiĭ, NB | 1 |
| Kostiuchenko, VG | 1 |
| Tereshchenko, LA | 1 |
| Tordiia, GD | 1 |
| De Deyn, PP | 2 |
| Reuck, JD | 1 |
| Deberdt, W | 1 |
| Vlietinck, R | 1 |
| Orgogozo, JM | 3 |
| Murphy, N | 1 |
| Kazek, MP | 1 |
| Van Vleymen, B | 2 |
| Melac, M | 1 |
| Souêtre, E | 1 |
| De Reuck, J | 2 |
| Huber, W | 1 |
| Coq, JO | 1 |
| Xerri, C | 1 |
| Bekuzarova, MR | 1 |
| Burd, GS | 1 |
| Kolesnikova, TI | 1 |
| Iasamanova, AN | 1 |
| Kabanov, AA | 1 |
| Trabant, R | 1 |
| Poljakovic, Z | 1 |
| Trabant, D | 1 |
| Godard, JP | 1 |
| Goerens, C | 1 |
| Grelier, C | 1 |
| Kometani, M | 1 |
| Okada, M | 1 |
| Takemori, E | 1 |
| Hasegawa, Y | 1 |
| Nakao, N | 1 |
| Inukai, T | 1 |
| Zozulia, IS | 1 |
| Zozulia, AA | 1 |
| Shevchenko, VA | 1 |
| Buslo, EA | 1 |
| Galusha, AI | 1 |
| Gottstein, U | 1 |
| Wade, JP | 1 |
| Amroian, EA | 1 |
| Vartazarian, ND | 1 |
| Parsamian, LK | 1 |
| Balian, LS | 1 |
| Eninia, GI | 1 |
| Purinia, IV | 1 |
| Robule, VKh | 1 |
| Maĭore, IKh | 1 |
| Timofeeva, TN | 1 |
| Berzina, AIa | 1 |
| Vesel'skiĭ, ISh | 1 |
| Voroniuk, MI | 1 |
| Dumas, M | 1 |
| Girard, PL | 1 |
5 reviews available for piracetam and Cerebrovascular Disorders
| Article | Year |
|---|---|
[Epilepsy in the elderly].
Topics: Aged; Aged, 80 and over; Aging; Amines; Anticonvulsants; Cerebrovascular Disorders; Comorbidity; Cyc | 2007 |
Pharmacotherapy for age-related behavioral deficiencies.
Topics: Adult; Aged; Aging; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Brain; Central | 1981 |
'Cerebroactive' drugs. Clinical pharmacology and therapeutic role in cerebrovascular disorders.
Topics: Adult; Aged; Cerebrovascular Disorders; Cinnarizine; Clinical Trials as Topic; Cytidine Diphosphate | 1983 |
The role of piracetam in the treatment of acute and chronic aphasia.
Topics: Acute Disease; Aphasia; Cerebrovascular Disorders; Chronic Disease; Humans; Nootropic Agents; Pirace | 1999 |
Multi-infarct dementia: prevention and treatment.
Topics: Cerebrovascular Disorders; Dementia, Multi-Infarct; Dihydroergotoxine; Humans; Hypertension; Naloxon | 1991 |
8 trials available for piracetam and Cerebrovascular Disorders
| Article | Year |
|---|---|
[The use of the combined drug vinpotropil at early stages of cerebrovascular insufficiency].
Topics: Aged; Aged, 80 and over; Calcium Channel Blockers; Cerebrovascular Disorders; Cognition; Dose-Respon | 2007 |
'Cerebroactive' drugs. Clinical pharmacology and therapeutic role in cerebrovascular disorders.
Topics: Adult; Aged; Cerebrovascular Disorders; Cinnarizine; Clinical Trials as Topic; Cytidine Diphosphate | 1983 |
Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group.
Topics: Acute Disease; Aged; Aged, 80 and over; Brain Ischemia; Cerebrovascular Disorders; Double-Blind Meth | 1997 |
Economic evaluation of Nootropil in the treatment of acute stroke in France.
Topics: Aged; Cerebrovascular Disorders; Cost-Benefit Analysis; Double-Blind Method; Female; France; Humans; | 1997 |
Acute treatment of stroke. PASS group. Piracetam Acute Stroke Study.
Topics: Cerebrovascular Disorders; Humans; Neuroprotective Agents; Piracetam; Prospective Studies | 1998 |
The clinical safety of high-dose piracetam--its use in the treatment of acute stroke.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Cerebrovascular Disorders; Double-Blind Method; Femal | 1999 |
[State of the hemostasis system and pathogenetic therapy of circulatory encephalopathy].
Topics: Adult; Age Factors; Aged; Benzamides; Blood Coagulation Tests; Central Nervous System Stimulants; Ce | 1997 |
[Effect of piracetam on the brain-organic psychosyndrome in cerebrovascular insufficiency. Results of a double-blind study in 40 cases].
Topics: Adult; Aged; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Blind Method; Drug Evaluati | 1977 |
17 other studies available for piracetam and Cerebrovascular Disorders
| Article | Year |
|---|---|
Coexistence of SARS-CoV-2 and cerebrovascular diseases: does COVID-19 positivity trigger cerebrovascular pathologies?
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clopidogrel; COVID-19; Enoxaparin; Humans; Manni | 2022 |
[Vinpotropile in the treatment of cerebral vascular diseases].
Topics: Administration, Oral; Adult; Blood Flow Velocity; Calcium Channel Blockers; Cerebrovascular Circulat | 2007 |
[The use of memotropil for treatment of mild cognitive impairment in out-patients with progressive chronic cerebrovascular disorders].
Topics: Aged; Ambulatory Care; Cerebrovascular Disorders; Chronic Disease; Cognition Disorders; Disease Prog | 2008 |
Experience of the out-patient use of memotropil in the treatment of cognitive disorders in patients with chronic progressive cerebrovascular disorders.
Topics: Aged; Ambulatory Care; Cerebrovascular Disorders; Chronic Disease; Cognition Disorders; Disease Prog | 2009 |
Two years of experience in the treatment of status epilepticus with intravenous levetiracetam.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Cerebrovascular Disorders; Epilepsies, | 2009 |
[The use of lucetam for improvement of cognitive functions in chronic cerebrovascular insufficiency (clinical and encephalographic study)].
Topics: Adult; Cerebrovascular Disorders; Chronic Disease; Cognition; Cognition Disorders; Disease Progressi | 2007 |
[Use of piracetam (nootropil) in the rehabilitative treatment of the middle-aged and elderly who have had a stroke].
Topics: Aged; Cerebrovascular Circulation; Cerebrovascular Disorders; Electrocardiography; Female; Hemodynam | 1980 |
Piracetam in the treatment of acute stroke.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aphasia; Cerebrovascular Disorders; Female; Humans; M | 1999 |
Acute reorganization of the forepaw representation in the rat SI cortex after focal cortical injury: neuroprotective effects of piracetam treatment.
Topics: Animals; Brain Mapping; Cerebrovascular Disorders; Child; Electrophysiology; Forelimb; Humans; Neuro | 1999 |
Usefulness of piracetam in intensive care.
Topics: Alcoholism; Brain Diseases; Brain Injuries; Carbon Monoxide Poisoning; Cerebrovascular Disorders; Ch | 1976 |
Effect of oxiracetam on cerebrovascular impairment in rats.
Topics: Animals; Behavior, Animal; Benzoquinones; Blood Pressure; Cerebral Arteries; Cerebral Infarction; Ce | 1991 |
[The treatment of hypertension patients with neurological disorders].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzothiadiazines; Cerebrovascular Disorders; | 1990 |
[Pathophysiology, clinical aspects and therapy of pre- and postoperative disorders of cerebral circulation and function].
Topics: Brain; Cerebrovascular Disorders; Epilepsy; Hemodynamics; Homeostasis; Humans; Neurocognitive Disord | 1990 |
[Effects of GABA and piracetam on the development of experimental cerebral infarction in rats and platelet aggregation in patients with cerebrovascular disorders].
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Brain; Cerebral Infarction; Cerebrovascular Disorders; | 1990 |
[Significance of subjective symptoms and diagnostic criteria in initial forms of cerebral circulation insufficiency].
Topics: Adolescent; Adult; Age Factors; Cerebrovascular Circulation; Cerebrovascular Disorders; Female; Hemo | 1989 |
[Effect of piracetam on cerebral hemodynamics in patients with arteriosclerosis and dyscirculatory encephalopathy].
Topics: Adult; Cerebrovascular Circulation; Cerebrovascular Disorders; Humans; Intracranial Arteriosclerosis | 1986 |
[Clinical study of piracetam in cerebral vascular accidents in black Africans].
Topics: Adult; Aged; Black People; Cerebrovascular Disorders; Female; Humans; Male; Middle Aged; Piracetam; | 1974 |